| Dr Mark Christopher Pohlman, MD | |
|
8 Prospect St, Nashua, NH 03060-3925 | |
| (603) 886-0290 | |
| (603) 577-3228 |
| Full Name | Dr Mark Christopher Pohlman |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 23 Years |
| Location | 8 Prospect St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700044641 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southern Nh Medical Center | Nashua, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foundation Medical Partners Inc | 9436140456 | 280 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386697803 PECOS PAC ID: 4183537509 Enrollment ID: O20031111000313 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
| Entity Name | Alliance Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891859419 PECOS PAC ID: 8022019215 Enrollment ID: O20070131000394 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Christopher Pohlman, MD Po Box 3677, Nashua, NH 03061-3677 Ph: (603) 577-7900 | Dr Mark Christopher Pohlman, MD 8 Prospect St, Nashua, NH 03060-3925 Ph: (603) 886-0290 |
News Archive
Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter ended March 31, 2010.
The substance wogonin triggers the death program apoptosis in tumor cells, while it has virtually no effect on healthy cells.
In 2010, Vemma donated over 60,000 bottles of Vemma NEXT, with a retail value in excess of $1.2 million, to Kids in Distressed Situations.
The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.
While the battle over the legality of the Affordable Care Act's mandate requiring most individuals to purchase health insurance continues to be fought, its impact on the quality and cost of care and what it would mean for patients and their physicians has been largely overlooked.
› Verified 9 days ago
Christopher Michael Riccio, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-594-6337 Fax: 603-594-6330 | |
Dr. Mark Liebling, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 166 Kinsley St Ste 301, Nashua, NH 03060 Phone: 603-883-5673 Fax: 603-689-1343 | |
Dr. Chengta Richard Dai, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 168 Kinsley Street, Suite 20, Nashua, NH 03060 Phone: 603-578-9363 Fax: 603-578-9539 | |
Dr. William Stephan, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 168 Kinsley St, Nashua, NH 03060 Phone: 603-889-4131 | |
Ihab M Ziada, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 173 Daniel Webster Hwy, Nashua, NH 03060 Phone: 603-891-4500 | |
Ajay K Sharma, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2039 Fax: 603-882-5656 | |
Dr. Gianfranco Tulliano, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2045 Fax: 603-577-5644 |